Kovaltry (Antihemophilic Factor [Recombinant]) is a clotting Factor VIII that has been developed in the laboratory and is very similar to the Factor VIII that occurs naturally in human blood.

People with hemophilia A do not have enough natural Factor VIII in their blood. Kovaltry gives them additional Factor VIII to help prevent and/or control bleeding.

Kovaltry is an intravenous medication, meaning it is given directly into the blood through an injection in a vein.